MediEmo移动应用程序的开发、实施及初步可行性测试:为医学辅助生殖提供支持
本研究采用混合方法,依据医学研究理事会复杂干预开发框架,于2013至2017年开发MediEmo智能手机应用,并于2017年6月至2020年9月在单一英国生育诊所实施,评估1106名潜在IVF周期参与者的可接受性与可行性。结果显示应用接受度良好(使用率79.8%),情绪数据灵敏可靠,医患反馈积极。
要点
- MediEmo应用整合用药管理、情绪管理和功能支持三大模块,共六项功能。
- 在1106名潜在IVF周期参与者中实施,使用率达79.8%,情绪数据灵敏可靠。
- 医患双方对应用反应积极,认为在繁忙诊所中实施可接受且可行。
核心结论
- 医患双方对MediEmo智能手机应用反应积极,认为其在繁忙诊所中可接受且可行。
研究设计与样本
- 混合方法研究,依据医学研究理事会复杂干预开发框架开发MediEmo应用。
- 开发于2013至2017年进行,实施于2017年6月至2020年9月在单一英国医学辅助生殖中心开展。
- 在1106名潜在参与IVF周期的参与者中评估可接受性与可行性。
主要发现
- MediEmo应用包含三项功能(六项特征):用药管理(用药时间线、消息传递)、情绪管理(情绪追踪、应对支持)和功能支持(常见问题、症状检查器)。
- 应用使用率为79.8%,情绪数据具有灵敏性和可靠性,反馈积极。
- 收集了用户年龄、生育诊断、抗苗勒管激素水平等数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 单中心研究。
- 问卷研究中的用户数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it possible to develop a patient smartphone application for medically assisted reproduction (MAR) that is acceptable to patients and fertility staff? SUMMARY ANSWER: Staff and patients responded positively to the MediEmo smartphone application, perceiving it to be acceptable and feasible to implement in a busy clinic. WHAT IS KNOWN ALREADY: Digital tools are increasingly popular to provide practical, administrative and psychological support alongside medical treatments. Apps and other digital tools have been developed for use alongside MAR but there is very limited research on the development or acceptability and feasibility of these tools. STUDY DESIGN, SIZE, DURATION: Mixed methods research. This article outlines the development phase of the MediEmo smartphone app, which was guided by the Medical Research Council development framework for complex interventions. The resulting MediEmo app was then implemented into a single centre for MAR in the UK, acceptability evaluated and feasibility explored among 1106 potential participants undertaking IVF cycles. PARTICIPANTS/MATERIALS, SETTING, METHODS: Consultation and data collection took part at a single mid-sized urban fertility clinic. Development of the MediEmo smartphone application took place during 2013 to 2017. Implementation of the MediEmo took place from June 2017 to September 2020. The MediEmo app comprises three functions (six features) namely medication management (medication timeline, messaging), mood management (emotional tracking, coping support) and functional support (frequently asked questions, symptom checker). Data on age, fertility diagnosis, anti-Müllerian hormone level were collected about the users of the MediEmo in addition to MediEmo usage data and attitudes towards the MediEmo smartphone application. MAIN RESULTS AND THE ROLE OF CHANCE: Informed by the developmental process described, MediEmo is an app combining patient medication diary management and ease of integration into clinic systems with emotional support, emotional tracking and data capture. This study demonstrates acceptability and feasibility of MediEmo, with good uptake (79.8%), mood data sensitivity and reliability and positive feedback. LIMITATIONS, REASONS FOR CAUTION: Single centre, small number of users in questionnaire studies. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest smartphone apps can contribute to fertility care and that patient engagement is high. Evaluation of any apps introduced into clinical pathways should be encouraged to promote development of the most useful digital tools for fertility patients. STUDY FUNDING/COMPETING INTEREST(S): This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. Outside of the submitted work, J.B. reports personal speaker fees from Merck KGaA, Darmstadt, Germany, Merck AB an affiliate of Merck KGaA, Darmstadt Germany, Theramex, MedThink China, Ferring Pharmaceuticals A/S, grant from Merck Serono Ltd, outside the submitted work and that she is co-developer of Fertility Quality of Life (FertiQoL) and MediEmo app; N.M and C.Y are minority shareholders and J.B.'s University (Cardiff University) owns one third of shares. None of the shareholders benefitted financially from MediEmo. I.R., C.H. and K.Y.B.N. declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Robertson I, Harrison C, Ng KYB, et al. Development, implementation and initial feasibility testing of the MediEmo mobile application to provide support during medically assisted reproduction. Hum Reprod. 2022. PMID: 35348672. doi:10.1093/humrep/deac046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。